ARTL RSI Chart
Last 7 days
3.7%
Last 30 days
5.3%
Last 90 days
-16.8%
Trailing 12 Months
-20.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 3.0K | 4.0K | 3.0K | 2.0K |
2021 | 699.1K | 559.7K | 420.3K | 141.4K |
2020 | 1.3M | 1.2M | 978.0K | 838.6K |
2019 | 735.0K | 852.6K | 1.2M | 1.3M |
2018 | 331.9K | 491.8K | 585.1K | 645.0K |
2017 | 75.4K | 98.7K | 121.9K | 220.1K |
2016 | 0 | 0 | 28.9K | 52.2K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 12, 2022 | gorgas gregory d. | bought | 4,800 | 4.00 | 1,200 | pres, ceo, cfo, treas & secr |
Aug 11, 2022 | gorgas gregory d. | bought | 4,836 | 4.03 | 1,200 | pres, ceo, cfo, treas & secr |
Apr 16, 2021 | gorgas gregory d. | bought | 9,809 | 1.154 | 8,500 | pres, ceo, cfo, treas & secr |
May 15, 2020 | gorgas gregory d. | bought | 5,071 | 1.2076 | 4,200 | pres, ceo, cfo, treas & secr |
May 04, 2020 | matsui connie | bought | 50,000 | 1.2 | 41,667 | - |
May 04, 2020 | gorgas gregory d. | bought | 5,000 | 1.2 | 4,167 | pres, ceo, cfo, treas & secr |
Nov 04, 2019 | gorgas gregory d. | bought | 5,303 | 2.2098 | 2,400 | pres, ceo, cfo, treas & secr |
Nov 01, 2019 | gorgas gregory d. | bought | 5,701 | 2.2807 | 2,500 | pres, ceo, cfo, treas & secr |
Oct 31, 2019 | gorgas gregory d. | bought | 4,874 | 1.9499 | 2,500 | pres, ceo, cfo, treas & secr |
Oct 30, 2019 | gorgas gregory d. | bought | 5,186 | 1.9948 | 2,600 | pres, ceo, cfo, treas & secr |
Which funds bought or sold ARTL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 1.35 | 481 | 7,205 | -% |
May 15, 2024 | Alpine Global Management, LLC | unchanged | - | -337 | 226 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 4.00 | 4.00 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 2.00 | 30.00 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -3.00 | 3.00 | -% |
May 14, 2024 | Verition Fund Management LLC | unchanged | - | -649 | 440 | -% |
May 14, 2024 | NewEdge Advisors, LLC | unchanged | - | - | 1.00 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | 2,179 | 29,712 | -% |
May 13, 2024 | UBS Group AG | new | - | 185 | 185 | -% |
May 13, 2024 | UBS Group AG | new | - | 75.00 | 75.00 | -% |
Unveiling Artelo Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Artelo Biosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Artelo Biosciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q4 | 2021Q3 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 76.00 | 151 | 226 | 198 | 195 | 193 | 304 | 215 | 266 | 433 | 354 | 210 | 167 | 121 |
Operating Expenses | -6.8% | 3,240 | 3,476 | 2,394 | 2,471 | 1,946 | 4,042 | 2,552 | 2,245 | 1,517 | 2,251 | 1,868 | 1,436 | 1,028 | 951 | 1,371 | 1,336 | 953 | - | - | - | - |
S&GA Expenses | -36.2% | 1,116 | 1,750 | 1,316 | 1,415 | 1,482 | 2,098 | 1,279 | 1,211 | 697 | 1,074 | 1,006 | 841 | 1,541 | 389 | 434 | 403 | 286 | 403 | - | - | - |
R&D Expenses | 23.1% | 2,124 | 1,726 | 1,078 | 1,056 | 464 | 1,944 | 1,273 | 1,034 | 933 | 951 | 663 | 595 | 272 | 259 | 721 | 667 | 234 | - | - | - | - |
Interest Expenses | - | - | - | 5.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 8.0% | -3,073 | -3,339 | -2,330 | -2,449 | -1,965 | -4,035 | -2,548 | -2,245 | -1,517 | -2,249 | -1,865 | -1,435 | -1,027 | -951 | -1,370 | -1,306 | -845 | - | - | - | - |
Net Income Margin | 7.9% | -4.64 | -5.04 | -3.59 | -2.75 | -3.60 | -5.17 | -60.54* | -29.43* | -18.36* | -14.07* | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -13.2% | -2,596 | -2,293 | -1,696 | -1,966 | -2,053 | -2,667 | -1,926 | -1,055 | -1,055 | -1,742 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Assets | -20.6% | 10,354 | 13,043 | 15,499 | 16,877 | 18,478 | 20,424 | 22,415 | 24,405 | 26,704 | 28,251 | 29,004 | 12,635 | 12,340 | 13,445 | 9,539 | 4,376 | 3,494 | 4,152 | 5,548 | 6,483 | 1,153 |
Current Assets | -25.4% | 8,188 | 10,980 | 13,428 | 14,602 | 16,386 | 18,322 | 20,303 | 22,282 | 24,589 | 24,609 | 25,355 | 10,317 | 10,300 | 11,405 | 7,500 | 2,337 | 1,453 | 2,111 | 3,508 | 4,443 | 1,152 |
Cash Equivalents | -57.5% | 1,195 | 2,815 | 2,639 | 5,719 | 6,916 | 6,888 | 7,136 | 12,122 | 10,350 | 12,162 | 14,047 | 6,629 | 10,052 | 10,706 | 7,389 | 2,142 | 1,279 | 1,983 | 3,375 | 4,424 | - |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | 63* | 124* | 185* | 246* | 1.00 | 2.00 | 598* | 721* | 857* |
Liabilities | -36.7% | 817 | 1,291 | 921 | 609 | 840 | 1,021 | 512 | 567 | 924 | 1,084 | 718 | 593 | 570 | 547 | 524 | 501 | - | - | - | - | - |
Current Liabilities | -44.2% | 721 | 1,291 | 921 | 603 | 825 | 998 | 480 | 527 | 875 | 1,027 | 659 | 526 | 424 | 589 | 486 | 501 | 268 | 444 | 585 | 1,022 | 1,019 |
Shareholder's Equity | -18.8% | 9,537 | 11,752 | 14,578 | 16,268 | 17,638 | 19,403 | 21,903 | 23,838 | 25,780 | 27,167 | 28,286 | 12,042 | 11,916 | 12,856 | 9,054 | 3,875 | 3,225 | 3,708 | 4,963 | 5,460 | - |
Retained Earnings | -6.2% | -42,793 | -40,310 | -37,237 | -34,788 | -33,189 | -31,021 | -27,682 | -25,352 | -22,903 | -20,938 | -19,451 | -16,903 | -15,015 | -12,766 | -10,900 | -9,466 | -8,438 | -7,487 | -6,117 | -4,810 | -3,965 |
Additional Paid-In Capital | 0.5% | 52,530 | 52,262 | 52,011 | 51,254 | 51,029 | 50,675 | 49,970 | 49,324 | 48,705 | 48,120 | 47,718 | 28,925 | 26,859 | 25,552 | 19,891 | 13,272 | 11,609 | 11,176 | 11,071 | 10,278 | 4,108 |
Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 886* | 792* | 646* |
Shares Outstanding | 1.2% | 3,228 | 3,189 | 3,162 | 2,856 | 2,856 | 2,856 | 2,856 | 2,840 | 2,820 | 2,820 | 2,820 | 1,635 | 1,543 | 1,481 | - | - | - | - | - | - | - |
Float | - | - | - | - | 5,630 | - | - | - | 13,685 | - | - | - | - | - | 39,891 | - | - | - | 2,970 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q4 | 2021Q3 | 2021Q3 | 2021Q2 | 2021Q2 | 2021Q1 | 2021Q1 | 2020Q4 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -13.3% | -2,942 | -2,596 | -1,802 | -1,623 | -2,186 | -2,293 | -1,696 | -1,966 | -2,053 | -2,667 | -1,926 | - | -1,055 | - | - | -1,742 | -945 | -1,874 | -1,320 | -872 | -1,020 |
Share Based Compensation | -2.7% | 213 | 219 | 222 | 225 | 354 | 608 | 607 | 619 | 624 | 934 | 571 | 502 | - | 609 | - | 519 | 323 | 70.00 | 51.00 | 55.00 | 53.00 |
Cashflow From Investing | -53.7% | 1,269 | 2,741 | -1,832 | 399 | 2,199 | 1,796 | -3,080 | 3,985 | 257 | -10,033 | -8,878 | - | - | -1,289 | - | -2,044 | 544 | -1,055 | - | 1.00 | - |
Cashflow From Financing | 71.9% | 55.00 | 32.00 | 535 | - | - | 134 | - | -134 | - | 18,261 | 18,262 | - | 890 | - | - | 6,009 | 5,320 | 6,578 | 6,579 | 1,710 | 283 |
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
OPERATING EXPENSES | ||
General and administrative | $ 1,082 | $ 1,057 |
Research and development | 1,507 | 1,235 |
Total Operating Expenses | 2,589 | 2,292 |
Loss from Operations | (2,589) | (2,292) |
OTHER INCOME | ||
Net change in fair value of trading marketable securities | 106 | 124 |
Total other income | 106 | 124 |
Provision for income taxes | 0 | 0 |
NET LOSS | (2,483) | (2,168) |
OTHER COMPREHENSIVE INCOME | ||
Unrealized gain on available-for-sale securities | 0 | 29 |
Foreign currency translation adjustments | 0 | 20 |
Total Other Comprehensive Income | 0 | 49 |
TOTAL COMPREHENSIVE LOSS | $ (2,483) | $ (2,119) |
Basic and Diluted Loss per Common Share | $ (0.78) | $ (0.76) |
Basic and Diluted Weighted Average Common Shares Outstanding | 3,197 | 2,856 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 1,195 | $ 2,815 |
Trading marketable securities | 6,414 | 7,611 |
Prepaid expenses and other current assets | 579 | 554 |
Total Current Assets | 8,188 | 10,980 |
Operating lease right-of-use assets | 124 | 21 |
Intangible asset | 2,039 | 2,039 |
Other assets | 3 | 3 |
TOTAL ASSETS | 10,354 | 13,043 |
Current Liabilities | ||
Accounts payable and accrued liabilities | 607 | 1,238 |
Due to related parties | 83 | 30 |
Operating lease liabilities - current portion | 31 | 23 |
Total Current Liabilities | 721 | 1,291 |
Operating lease liabilities | 96 | 0 |
TOTAL LIABILITIES | 817 | 1,291 |
STOCKHOLDERS' EQUITY | ||
Preferred Stock, par value $0.001, 416,667 shares authorized, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common Stock, par value $0.001, 50,000,000 shares authorized, as of March 31, 2024 and December 31, 2023 3,227,700 and 3,188,959 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 3 | 3 |
Additional paid-in capital | 52,530 | 52,262 |
Accumulated deficit | (42,793) | (40,310) |
Accumulated other comprehensive loss | (203) | (203) |
TOTAL STOCKHOLDERS' EQUITY | 9,537 | 11,752 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 10,354 | $ 13,043 |